Skip to main content

New story in Health from Time: CVS Halts Sale of Heartburn Treatment Zantac as FDA Warns of Contaminants



CVS has halted sales of popular heartburn treatment Zantac and its generic store brand after warnings by U.S. health regulators.

It’s the latest precautionary move by retailers and manufacturers after the U.S. Food and Drug Administration recently warned consumers about a potentially dangerous contaminant in prescription and over-the-counter versions of Zantac.

In its announcement this weekend, CVS said customers who bought Zantac products can return them for a refund. The retailer will continue to sell other heartburn medications.

What’s the issue?

In September, the FDA said it detected low levels of a probable cancer-causing chemical known as NDMA in Zantac and related generic drugs to treat ulcers and reflux disease. The same chemical has been linked to dozens of recalls of prescription blood pressure drugs in the past year.

The agency said the amount found in Zantac products barely exceeds levels found in common foods such as meats, dairy products and chemicals. Even so, the warning has led some pharmacies and manufacturers to stop selling drugs containing Zantac’s active ingredient, ranitidine.

What’s the reaction?

CVS Health said Saturday it has pulled Zantac and its generic store brand, saying the move “is being taken out of an abundance of caution.” On Monday, Rite Aid said it’s removing Zantac and related drugs sold under its name from its shelves. Walgreens earlier said it’s removing Zantac products from shelves while the FDA continues its investigation.

Last week, two generic makers voluntarily recalled their products: Apotex and Sandoz, the generic unit of drug giant Novartis AG. Both companies said they haven’t received any reports of patient harm. Some other manufacturers have stopped shipping their product to pharmacies.

The recalled Apotex products are sold at and labeled by Walgreens, Walmart and Rite-Aid, according to the FDA.

Sanofi, which makes brand name Zantac, said Monday it’s working with the FDA and doing its own investigation. But it has not stopped selling Zantac in the U.S.

The FDA has asked makers of ranitidine medications to test levels of NDMA in their products and to send samples to the agency.

What’s the advice for patients?

Currently, the FDA isn’t advising patients to stop taking Zantac and related drugs. The agency said not all ranitidine medicines sold in the U.S. are being recalled. Concerned patients should contact their doctor.

Are there alternatives?

Several drugs also treat heartburn and other stomach conditions. They include Pepcid, Nexium, Prilosec, Prevacid and Protonix. Some are available only with a prescription, while others also have less-potent nonprescription versions. For people taking over-the-counter Zantac and related medications, the FDA recommends they consider another heartburn medicine.

Popular posts from this blog

New story in Health from Time: COVID-19 Has Been ‘Apocalyptic’ for Public Transit. Will Congress Offer More Help?

While trying to get to work over the past few months, Brittany Williams, a Seattle home care worker, has often been passed by two or three buses before one stops to let her board. Buses in her area that once carried anywhere from about 50 to 100 passengers have been limited to between 12 and 18 to prevent overcrowding in response to coronavirus, and Williams’ commute, typically a half-hour ride, now takes more than double that time. Other Seattle transit riders have described budgeting as much as an extra hour per trip to account for the reduced capacity, eating into their time at work, school or with family. Even with the ridership limits in place, Williams, 34, doesn’t feel safe on public transit. Some passengers don’t wear face coverings, and bus drivers sometimes ignore capacity limits, she says. On one ride with her seven-year-old son, she decided to get off at a stop far from her home after a driver allowed a crowd of people to board. “It’s very trying. I’ll put...

New story in Health from Time: An At-Home Coronavirus Test May Be On the Way in the U.S.

As cases of COVID-19 continue to climb in the U.S. , there’s a new urgency to make sure there are as many tests as possible to diagnose people who have symptoms that might indicate an infection. Knowing if people are positive is important for guiding their next steps: self-isolation, avoiding contact with others, and, if their symptoms get worse, seeking medical care. To date, access to tests has been spotty at best across the country, and while more kits are now available than even a week ago , most are gene-based assays that take several days for commercial labs to process and produce results. That may change in about two months if the Food and Drug Administration (FDA) gives Emergency Use Authorization to the first blood-based COVID-19 test in the U.S. Scanwell Health, an at-home test company based in California, licensed the rights to a test developed by Chinese company Innovita, which was used extensively at the height of country’s epidemic earlier this year. “The ...

New story in Health from Time: A Montana Care Home Refused Free COVID-19 Tests. Now, Nearly Every Resident Has Coronavirus

(BILLINGS, Mont.) — It was meant to be a last line of defense to protect the most vulnerable as the coronavirus spread across the United States : Montana officials offered free testing in May for staff and residents at assisted living and long-term care facilities. But not all of them followed through, according to state data, including a facility in Billings, Montana’s largest city, that cares for people with dementia and other memory problems. The virus has infected almost every resident and killed eight, accounting for almost a quarter of Montana’s 34 confirmed deaths. Thirty-six employees also have tested positive at the facility where 59 people lived before the deaths began. Read more: ‘It’s Getting Worse.’ Nursing Home Workers Confront Risks in Facilities Devastated by Coronavirus While Montana’s rates of confirmed infections and deaths are much lower than other parts of the country, the outbreak at Canyon Creek Memory Care illustrates that even the most simple an...